glp 1 agonist uses glp-1_analogs [TUSOM The current significance and prospects
Description
On April 1, 2026, the FDA approved Eli Lillys FOUNDAYO (orforglipron) , the second oral GLP-1 approved for obesity, and arguably the one with the more patient-friendly convenience profile
Get started $50 off Wegovy GLP-1SemaglutideIn stock Lose up to 15% of body weight Weekly injectable pen FDA-approved medication for weight loss Use code at checkout $1,599/mo thereafter
Samms RJ, Kusminski CM
The development of GLP-/GIP dual agonists provides a more complete scheme for the treatment of metabolic diseases, but the safety of more dual agonists or multiple agonists in clinical trials is also worthy of attention
aHR, adjusted hazard ratio
In the SURMOUNT-1 trials, the tirzepatide group lost about 20.2% of baseline body weight in 72 weeks, while the semaglutide group lost about 13.7 %
